Pharmaceutical

Pfizer is initiating a $500 million expansion of its Sanford campus with the construction of a 100,000-sf gene therapy facility. Supporting the creation of innovative treatments for genetic diseases, the project will feature advance manufacturing technologies for clinical and commercial-scale production of recombinant adeno-associated virus (rAAV) vectors. Accommodating 300 new employees, the facility will complement operations at the existing 628,000-sf Sanford complex and at the company's Chapel Hill and Kit Creek locations.

Amgen broke ground in late July of 2019 on a $200 million biomanufacturing center in West Greenwich, R.I. Featuring a highly flexible, modular design, the next-generation facility will leverage advanced technologies to reduce operational expenses, consume 80 percent less energy and water, and achieve a 75 percent decrease in carbon emissions.

HALIX is constructing a 72,000-sf cGMP facility at Leiden Bio Science Park in the Netherlands. Utilizing 1000-liter, single-use bioreactors, the five-story building will accommodate the development and manufacture of biopharmaceutical drug substances for clinical and commercial applications. Housing labs for process development, analytical development, and quality control, the structure will feature cleanrooms with unidirectional process flows with separate areas for protein manufacturing and the production of viral vaccines and viral vectors.

Adaptive Biotechnologies is expanding its presence in Seattle with the lease of a 100,000-sf headquarters building in Seattle. The lab and office facility is located in the Lake Union life science district and is being developed by Alexandria Real Estate Equities. Adaptive will occupy the entire structure, which is sited adjacent to its existing facility. Building amenities will include an open-air plaza, a rooftop desk, a fitness center, locker and shower rooms, and direct access to water sports on Lake Union.

Foundation Medicine will locate its 580,000-sf life science headquarters in a planned 625,000-sf building in Boston's Seaport Square. Designed by Morris Adjmi Architects and Stantec, the leased building will provide leading-edge research, collaboration, and administrative facilities to support the creation of innovative biomedical therapies.

Procter & Gamble is engaged in a $50 million renovation and expansion of the Reading Gillette Innovation Centre in the United Kingdom. The project includes the construction of new research labs and the renovation of an existing building and associated warehouses to create a two-story, 75,300-sf complex to house the Health Care Innovation Laboratories. Completion is expected in late 2019 with occupancy in 2020.

ADC Bio completed construction of a £5 million bioconjugation cleanroom in July of 2019. Located within the company's 70,000-sf facility in Deeside in the United Kingdom, the GMP lab will support the commercial manufacture of innovative antibody-drug conjugates for the treatment of cancer. Designed and constructed by WHP Engineering, the project houses Grade C and D cleanrooms with four-zone HVAC systems for optimal environmental containment.

The University of Cambridge will break ground in November of 2019 on the Heart and Lung Research Institute in Cambridge in the United Kingdom. Sited adjacent to the Royal Papworth Hospital on the Cambridge Biomedical Campus, the facility will accommodate 380 academic and industry scientists engaged in the discovery of new therapeutics and diagnostic tools for cardiovascular conditions.

NeoGenomics will break ground in late 2019 on a $55 million oncology laboratory and global headquarters facility in Fort Myers, Fla. Designed by Studio Plus, the 150,000-sf facility will provide the comprehensive cancer diagnostics company with research and administrative space for up to 575 employees. Located on a 14-acre parcel, the building will support clinical trials of new oncology therapeutics with a state-of-the-art molecular lab with next-generation sequencing capabilities.

Nexus Pharmaceuticals will begin construction in August of 2019 on a $250 million manufacturing complex in Pleasant Prairie, Wis. The multi-phase project will be delivered over the next ten years, enabling Nexus to expand its production capacity for sterile injectable drugs. The first phase comprises an $85 million manufacturing building featuring an advanced isolator system and multiple lyophilization machines. The three-story, 84,450-sf structure was designed by Integrated Project Services and will be built by Turner Construction.

Eli Lilly and Company is building a 45,000-sf headquarters facility in Basingstoke in the United Kingdom. Located in the Basing View Enterprise Zone, the project is being built by Muse Developments with Morgan Sindall Construction as general contractor. Designed by TP Bennett, the facility will provide open offices, conference rooms, and collaboration spaces to support the production of Eli Lilly's innovative pharmaceutical therapies. The leased building will be owned by the Basingstoke and Deane Borough Council.

Tergus Pharma began construction in July of 2019 on a cGMP commercial manufacturing facility in Research Triangle Park in North Carolina. An existing 100,000-sf building will undergo renovation to become the company's headquarters, providing production suites, laboratories, offices, packaging lines, and a GMP warehouse. The $35 million project will also include a clinical trial materials manufacturing space and suites for the creation of high-potency compounds and hormones. Completion is expected in early 2020.

ElevateBio has selected DPS Group and TRIA to design ElevateBio BaseCamp, a 108,000-sf cGMP development and manufacturing facility in Waltham. Located in a 430,000-sf office and lab building, the facility will offer integrated R&D, process development, and cGMP manufacturing services for novel therapeutic technologies.

Aldevron will begin construction in August of 2019 on a 14-acre biologics campus in Fargo, N.D., where it is currently headquartered. The first phase comprises a two-story, 189,000-sf facility for the manufacture of plasmid DNA, proteins, mRNA, and antibodies. Increasing Aldevron’s GMP and GMP-Source™ production capacity up to tenfold, the structure will connect to the company's existing GMP facility and is expected to be fully operational by early 2021.

WuXi Biologics began construction in May of 2019 on a $365 million pharmaceutical production facility in Dundalk, Ireland. Sited on 52 acres, the 522,000-sf contract manufacturing center will utilize single-use technologies and processes, enabling cost-effective scale-out and the simultaneous production of multiple batches of varying volumes. Commercial operations are expected to begin in 2022 at the site, which will be the company's first manufacturing plant outside of China.